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Abstract
Various studies have presented clinical or in vitro evidence linking bacteria to colorectal cancer,
but these bacteria have not previously been concurrently quantified by qPCR in a single cohort.
We quantify these bacteria (Fusobacterium spp., Streptococcus gallolyticus, Enterococcus
faecalis, EnterotoxigenicBacteroides fragilis (ETBF), Enteropathogenic Escherichia coli
(EPEC), and afaC- or pks-positive E. coli) in paired tumour and normal tissue samples from 55
colorectal cancer patients. We further investigate the relationship between a) the presence and
b) the level of colonisation of each bacterial species with site and stage of disease, age, gender,
ethnicity andMSI-status. With the exception of S. gallolyticus, we detected all bacteria profiled
here in both tumour and normal samples at varying frequencies. ETBF (FDR = 0.001 and 0.002
for normal and tumour samples) and afaC-positive E. coli (FDR = 0.03, normal samples) were
significantly enriched in the colon compared to the rectum. ETBF (FDR = 0.04 and 0.002 for nor-
mal and tumour samples, respectively) and Fusobacterium spp. (FDR = 0.03 tumour samples)
levels were significantly higher in late stage (III/IV) colorectal cancers. Fusobacteriumwas by
far themost common bacteria detected, occurring in 82% and 81% of paired tumour and normal
samples. Fusobacteriumwas also the only bacterium that was significantly higher in tumour
compared to normal samples (p = 6e-5). We also identified significant associations between
high-level colonisation by Fusobacterium andMSI-H (FDR = 0.05), age (FDR = 0.03) or pks-
positive E. coli (FDR = 0.01). Furthermore, we exclusively identified atypicalEPEC in our cohort,
which has not been previously reported in association with colorectal cancer. By quantifying co-
lorectal cancer-associated bacteria across a single cohort, we uncovered inter- and intra-indi-
vidual patterns of colonization not previously recognized, as well as important associations with
clinicopathological features, especially in the case of Fusobacterium and ETBF.
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Introduction
A causal link between specific pathogens and numerous cancers has now been firmly estab-
lished. Clear evidence exists for example that the vast majority of cervical cancers are directly
caused by infection with human papillomavirus (HPV) [1]. Similarly, Helicobacter pylori is a
known risk factor for the development of gastric cancer and is considered a class I carcinogen
by the WHO [2,3].
The possibility of oncogenic bacteria in the colon was already evident in the 1950s when a
clinical association between Streptococcus bovis bacteraemia/endocarditis and CRC was discov-
ered [4]. Subsequently, multiple studies have demonstrated enrichment with specific bacterial
pathogens in faecal or tissue samples of CRC patients, including, Fusobacterium spp. [5–7],
S. gallolyticus [8–10], E. faecalis [11] and Enterotoxigenic Bacteroides fragilis (ETBF) [12].
Previously, 16S rRNA profiling of colorectal cancer (CRC) paired tumour and normal biop-
sies has revealed that while only 3% of biopsy specimens from healthy controls contained any
type of bacteria, ~90% of patients with adenomas or carcinomas had 103–105 bacteria in both
malignant and macroscopically normal samples [13]. This clearly demonstrates the susceptibil-
ity of these patients to colonisation of the normally sterile colonic epithelium––not only in ex-
isting tumour tissue, but also in the surrounding macroscopically normal tissue, which may
suggest a pre-existing risk to colonisation/infection.
Based on both in vitro and in vivo observations, bacterially-driven oncogenic mechanisms
in CRC have been proposed to include activation of Wnt signaling (ETBF [14], Enteropatho-
genic Escherichia coli (EPEC) [15], Fusobacterium [16]), pro-inflammatory signaling (E. faeca-
lis [17,18], S. gallolyticus [19,20]) and genotoxicity (EPEC [21], AIEC [22–24]).
The oncogenic potential of these bacteria, as well as suspected bacterial components impli-
cated in the aetiopathogenesis of CRC, are summarized in Table 1.
To date, however, the presence and levels of multiple CRC-associated bacteria have not
been examined across a single cohort. Further, to our knowledge, ETBF and E. faecalis have
only been quantified by quantitative PCR (qPCR) in feacal samples of CRC patients, and EPEC
has only been quantified in a small CRC cohort with archival FFPE samples [25].
Here we use qPCR to measure the presence of six pathogens, previously reported in associa-
tion with CRC, in paired adenocarcinoma and adjacent normal mucosal samples; these include




This study consists of two cohorts: Firstly 55 paired colorectal patient samples (adenocarcinoma
tissue and adjacent normal mucosa) were collected during surgical resection at the Groote
Schuur Hospital, with no pre-selected conditions. Ethical consent was obtained (UCT HREC
REF 366/2010) and each patient provided written informed consent to donate samples from the
tissues left over after surgical resection to subsequent molecular studies. The second cohort was
sourced in order to obtain more patients with sporadic microsatellite instability (MSI). For this
cohort, 18 adenocarcinoma samples were selected from archival FFPE specimens that had previ-
ously been screened for MSI by immunohistochemistry of the mismatch repair genesMLH1,
MSH2 andMSH6; these patients were referred for MSI testing because CRC was diagnosed
under the age of 50 and/or in two or more first or second degree relatives with an HNPCC-relat-
ed tumor, regardless of age. For our purpose, we selected patients with MSI (absence of staining
of one or more MMR proteins), whom also had mutational screening data available so that we
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could distinguish between sporadic and HNPCC-based MSI. Of the 18 patients selected two had
confirmed mutations in theMLH1mismatch repair gene, and were therefore classified as
HNPCC. Detailed participant-level characteristics are presented in S1 Table.
DNA extraction
DNA was isolated from paired patient samples using a Dounce homogenizer and the AllPrep
DNA/RNA/Protein kit (Qiagen) according to the manufacturer’s instructions; for the detection
of gram-positive bacteria DNA was extracted using the QIAamp DNAMini Kit (Qiagen).
DNA was extracted from ± 25mg of tissue, using the following protocol: each sample was incu-
bated in 180 μl lysozyme @ 20mg/ml for 40 min at 37°C; after adding 20 μl proteinase K, sam-
ples were incubated at 56°C until the tissue was completely lysed (at least 4 hours, or overnight
if tissue was still visible after 4 hours); samples were next incubated for 30 min in Buffer AL,
thereafter, DNA was isolated according to the manufacturer’s instructions. DNA integrity was
confirmed in each case by gel analysis (Agilent BioAnalyser 2100; data not shown). For FFPE
samples, DNA was extracted from one or two FFPE slides (depending on availability) using the
RecoverAll Total Nucleic Acid Isolation Kit (Ambion). After deparraffinization, samples were
incubated in 180 μl lysozyme (20mg/ml) for 40 min at 37°C, followed by incubation for
42 hours at 50°C in Proteinase K. For the remainder of the protocol DNA was isolated accord-
ing to the manufacturer’s instructions.
MSI testing
For the cohort of fresh-frozen samples, MSI analysis was conducted on DNA extracted from
paired tissue samples as well as the corresponding blood samples for each patient, using allelic
profiling of the Bethesda panel of microsatellite markers (BAT25, BAT26, D2S123, D5S346,
and D17S250), using primers specified by Loukola et al. [34]. Samples were classified as micro-
satellite stable (MSS), microsatellite instable-low (MSI-L) or microsatellite instable-high (MSI-
H) if they had 0, 1 or at least 2 of the 5 markers showing instability, respectively [35].
Table 1. Summary of the putative oncogenic mechansims and the bacterial components implicated in CRC pathogenesis for the six bacterial
species quantified in this study.




Downregulates mismatch repair proteins in vitro [21,25]; increases mutational
frequency in vitro [21].
espF [21]
Escherichia coli with adherent/and
or invasive properties.
Enriched in CRC patients [13,26,27]; CRC-associated strains commonly have
genes related to M-cell translocation (lpfA) [22]; genotoxicity (pks) [22–24,28],
or cell cycle modulation (cnf1) [23].
pks [22–24], afaC [22], lpfA[22]
cnf1 [23] and cdt [23].
Fusobacterium spp. Multiple independent metagenomic studies identify Fusobacterium spp. as
overrepresented in CRC tissue compared to matched normal mucosa and
healthy controls [5–7]. F. nucleatum increases tumour multiplicity in an APC




Enriched in faecal samples from CRC patients [12]; Triggers ß-catenin nuclear
signaling; induces c-Myc expression and cellular proliferation [14]; increases
colitis and tumour in a Min/+ mice model [30].
B. fragilis toxin (Bft)[14]
Streptococcus gallolyticus Enriched in CRC patients with [8–10,31] and without bacteremia [9]. S.
infantarius or its wall extracted antigens promote progression of preneoplastic
lesions in rats and promotes pro-inflammatory COX-2 signaling [19,20].
Cell wall extracted antigens
Enterococcus faecalis Enriched in faecal samples from CRC patients [11]; Produces extracellular
superoxide [32], promotes inflammation and CRC in IL-10 knockout mice
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For the FFPE cohort, immunohistochemistry (IHC) had previously been performed for
MSH2, MSH6 and MLH1 by the Division of Anatomical Pathology, University of Cape Town.
Samples that displayed absence of staining for any of the mismatch repair proteins evaluated
were considered MSI-H since IHC has been shown to have high sensitivity (92.7%) and speci-
ficity (100%) in detecting MSI [36]. Originally, patients were referred for IHC based on the fol-
lowing criteria: 1) Colorectal cancer diagnosed under the age of 50 years of age and 2)
Colorectal cancer diagnosed in two or more first or second degree relatives with an HNPCC-
related tumor, regardless of age.
Primers and control DNA
Primers for the detection of each bacterial species were sourced from the literature or designed
in-house, and their specificity was confirmed using Primer BLAST [37]. All primers, along
with their limits of detection (LODs) and qPCR efficiencies, are listed in S2 Table.
The following reagents were obtained through the NIH Biodefense and Emerging Infections
Research Resources Repository, (NIAID, NIH) as part of the Human Microbiome Project:
Streptococcus gallolyticus subsp. gallolyticus, Strain TX20005, HM-272D; Genomic DNA from
Bacteroides fragilis, Strain 3_1_12, HM-20D, Genomic DNA from Clostridium difficile, Strain
NAP07 (CDC#2007054), HM-88D; Genomic DNA from Enterococcus faecalis, Strain HH22,
HM-200D; Genomic DNA from Escherichia coli, Strain B171, NR-9297; and Genomic DNA
from Fusobacterium nucleatum subsp. polymorphum, Strain F0401. ETBF genomic DNA
(ATCC43858) was kindly provided by Dr Annalisa Pantosti from the Istituto Superiore di
Sanità, Italy. DNA from enterohemorrhagic E. coli (to confirm EPEC identity) was kindly sup-
plied by Dr. Anthony Smith at the National Institute for Communicable Diseases, South Africa.
DNA from AIEC (strains HM358, HM229 and HM334) was kindly provided by Dr. Barry
Campbell from the University of Liverpool, UK.
qPCR amplification conditions
Experiments were performed in triplicate on a Roche LightCycler 480 Real-Time PCR System
in 96-well format, using 50 ng patient DNA per well. Separate assays were performed for each
bacterial gene detected; the cycling conditions are specified in S3 Table. EPEC (eaeA, bfpA and
stx1 and stx2), ETBF and S. gallolyticus, were each detected in 20 μl reactions using SensiFAST
SYBR No-ROX Kit (Bioline); AIEC, Fusobacterium spp. and E. faecalis were each detected in
25 μl reactions using Maxima SYBR green qPCRMaster Mix (Thermo Scientific). In order to
increase specificity, it was necessary in some cases to perform touchdown PCR, whereby the
annealing temperature is lowered in a stepwise manner to discourage amplification of off-tar-
gets during the first 10 cycles of PCR [38]; Touchdown qPCR was performed for detection of
EPEC (bfpA and eaeA), S. gallolyticus, ETBF, EHEC (stx1 and stx2) and AIEC (afaC).
qPCR quantification
For each qPCR assay, absolute quantification was performed using a standard curve, which
was constructed using serially diluted genomic DNA from the relevant positive control strain.
The concentration of bacterial DNA found was expressed in terms of genome copies by calcu-
lating the weight of one genome copy for each species as used by Dolezel et al.[39]: DNA con-
tent (pg) = genome size (bp)/(0.978 x 109).
For example, Fusobacterium spp. have an estimated genome size of 2.2 Mb and since one
molecule of double stranded DNA of length 978 Mb weighs approximately one picogram, a
single Fusobacterium spp. genome weighs approximately 2.25 fg (2.2Mb/978Mb = 0.00225 pg)
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and therefore 1 ng of DNA from Fusobacterium spp. equates to 444,545 copies (1000pg/
(2.2Mb/978Mb)) of the bacterium (Table 2).
In the case of AIEC strains, genome size may vary substantially between strains, since these
strains are classified according to phenotypic traits and not sequence similarity. We opted to
use the prototypical LF82 AIEC strain, which has a genome size of 4.88 for quantification.
In all cases, data were normalised to total genomic DNA and represented as number of bac-
terial genomes per 50 ng human DNA, thereby effectively normalising the qPCR data to
tissue size.
Positive control standards were spiked with the same amount of human genomic DNA (ex-
tracted from uninfected human cell cultures) as used in the patient sample reactions (50ng).
The limit of detection (LOD) was defined as the lowest concentration at which a positive result
(correct meltcurve) could be obtained in at least 50% of replicates (see S2 Table for details). For
all assays except ClB and afaC at least 70% of replicates were positive at the relevant LOD. In
cases where results were inconsistent (1/3 replicates positive), samples were retested and taken
as positive if a positive meltcurve was obtained in both runs (the results were then averaged
across the two runs to obtain quantitative data).
qPCR quantification in FFPE samples
We first evaluated the quality of DNA extracted from archival FFPE slides (which had been
stored between 2 and 23 years) using three primer pairs designed to amplify 100bp, 200bp and
300bp amplicons of the GAPDH gene [44]. For most samples we detected either a very faint or
no visible band at 100bp; whilst a 200bp amplicon could only be amplified in a few samples.
On testing a shorter amplicon (69bp) of the COX1 gene (which we found to be stably expressed
in our cohort and is therefore assumed to have no significant differences in copy number be-
tween samples), all samples could be amplified by qPCR; the difference in cycle threshold (Ct)
between the highest and lowest quality sample was 9.3. We therefore redesigned the reverse
primers for bacterial detection to shorten the resulting amplicons to 60–70bp, and used the
cox1 results to account for degradation in our bacterial quantification. In the case of eaeA, two
reverse primers were designed, one that detects intimin subtypes epsilon, gamma, zeta, alpha,
pi, rho, beta, lambda, iota, kappa, eta, delta, xi, mu, kappa and jota; while the second was de-
signed to specifically detect intimin theta (which was found in both EPEC-positive MSI-H
samples from the fresh-frozen cohort). The efficiencies for the COX1 qPCR was calculated
using 5-fold serial dilutions constructed using for a high- and low quality patient sample, as
1.96 and 2, respectively. A ‘fold change’ value was then calculated for COX1 in each sample,
using the ΔΔCt method and the mean Ct across 6 randomly selected DNA samples from the
fresh-frozen (high-quality DNA) sample cohort was used as reference (the maximum ΔCt be-
tween fresh-frozen samples was 1.8). These sample-specific ‘fold change’ values for COX1 be-
tween FFPE samples to be tested and the reference set of fresh-frozen samples were used as a
correction factor to adjust for DNA sample quality. A theoretical limit of detection was also cal-
culated for each sample by multiplying the correction factor for each sample with the LOD that
had previously determined for high quality DNA. After performing absolute quantification,
the result was multiplied by the correction factor for each sample. The validity of this method
was assessed by comparing Fusobacterium quantitation obtained from DNA extracted from
fresh frozen samples to that of the matched FFPE samples (which we had available for four pa-
tients); after removing a single outlier sample, the Pearson’s correlation coefficient was 0.94,
and the median fold change between matched fresh-frozen and FFPE samples was 1. FFPE
samples that tested negative for Fusobacterium were set to ‘NA’ for downstream analysis, since
the negative results could be due either to sample quality or to absence of the bacterium.
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Statistical analyses
In order to assess quantitative differences between paired tumour and normal samples for each
bacterium, we used the Wilcoxon signed rank test applied to the subset of samples, which had
at least one positive sample in a pair (tumour or normal).
To assess the association between each bacterium and clinicopathological features, we com-
pared a) samples with vs. without colonisation by a particular bacterium and b) samples with
high vs. low/no-colonisation by a particular bacterium. Except for Fusobacterium, all other bac-
terial quantitative data suffered from zero-inflation due to the large number of colonisation-
negative patients, which lead to unequal variances between groups. We therefore converted the
quantitative data to categorical data where for each bacterium, samples were categorised as
‘no-colonisation’, ‘low-colonisation’ or ‘high-colonisation’. Quantitative data (copies/50ng)
were log2 transformed and samples with no-colonisation were arbitrarily set to 1 before log2
transformation; the third quartile (calculated across colonisation-positive cases only) was used
to discriminate low- and high-colonisation cases (see Fig. 1 for categories). Associations with
clinicopathological features were examined using Fisher’s exact test. Meanwhile, in the case of
Fusobacterium (where the data was normally distributed), we used the Kruskal-Wallis test to
evaluate differences between groups stratified by the clinicopathological parameter of interest.
Results with an FDR 0.05 after applying multiple-testing-correction (Benjamini-Hochberg




The clinicopathological characteristics of the patients in cohort 1 (fresh-frozen samples) are
summarized in Table 3. Briefly, the mean age of patients was 59 (SD±15.3), while gender was
divided equally. The samples for which MSI-testing was performed (N = 23) included 7 MSI-H
(including 4 HNPCC patients) and 3 MSI-L patients. The majority of cases were stage II or III
cancers (81.6%), while stage I and IV cancers accounted for 12.2% and 6.1% of cases, respec-
tively. The cohort consists of 60% rectal and 40% colon cancers, with proximal cancers ac-
counting for 45% of the colon cancers. Further, the majority of our cohort is mixed-ancestry
(70.4%), while patients of caucasian (14.8%), black (11.1%) and indian ethnicities (3.7%) made
up the rest of the cohort.
Table 2. Estimates of bacterial genome copies per nanogram of bacterial DNA.
Strain, genome
size
Number of target gene copies/genome
assumed.
Estimated bacterial copies/ng bacterial
DNA.
EPEC (eaeA/bfp) E2348/69, 4.97 Mb 1 2 x 105
ETBF (bft) 3_1_12, 5.49 Mb 1 1.8 x 105
E. faecalis (16s rRNA) V583, 3.34 Mb 4[40] 1.2 x 106
Fusobacterium spp. (16s
rRNA)
NA, 2.8 Mb[41] 5[41] 1.8 x 106
AIEC (afaC) LF82, 4.88 Mb[42] 1 2 x 105
AIEC (ClB) LF82, 4.88 Mb 1 2 x 105
S. gallolyticus (sodA) UCN34, 2.35[43] 1 4 x 105
EHEC (stx1) O157:H7, 5.6 1 1.8 x 105
EHEC (stx2) O157:H7, 5.6 1 1.8 x 105
doi:10.1371/journal.pone.0119462.t002
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Given the association between EPEC and MSI demonstrated by Maddocks et al.[25] and
here, as well as the reported association between the levels of colonization by Fusobacterium
spp. and MSI status, since we had limited numbers of MSI-H samples in the original fresh-
frozen cohort, we sourced additional MSI-H samples in order to increase statistical power to
measure the relationship between Fusobacterium or EPEC and MSI status. To do this, we lever-
aged archival FFPE samples from Groote Schuur Hospital, Cape Town, South Africa, for which
immunohistochemistry of the mismatch repair genes MLH1, MSH2 and MSH6 had been
conducted previously.
Bacterial quantification
We quantitated CRC-associated bacteria in adenocarcinoma and matched normal mucosal
samples by qPCR, using a serial dilution of genomic DNA from each bacterium as standards,
and found varying levels of colonisation in tumour and/or adjacent normal mucosa for all
bacteria measured, except S. gallolyticus, for which no positive samples were found. While the
association between S. gallolyticus bacteremia or infective endocarditis and CRC is well estab-
lished [10], we found only one study, by Abdulamir et al. [9], where S. gallolyticus was mea-
sured in CRC patients without a history of bacteremia or infective endocarditis. That study
found that 4% of healthy controls but 48.7% and 32.7% of CRC patients with or without bac-
teremia were infected with S. gallolyticus in the relevant colonic tissue [9]. In contrast, we did
Fig 1. Levels of colonization by each bacterium/gene were categorized using the third quartile (taken across colonisation-positive samples) as a
cutoff for high- or low-level colonisation.Categories: 1 (No colonisation), 2 (low colonisation), 3 (high colonisation). In the case of EPEC, because there
were so few EPEC-positive patients (N = 6), samples were analysed as positive or negative only. EF: E. faecalis; FB: Fusobacterium.
doi:10.1371/journal.pone.0119462.g001
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not detect S. gallolyticus in any of our adenocarcinoma or matched normal mucosa samples
using the same primers used by Abdulamir et al. [9] for conventional PCR and qPCR. We
note that the levels reported in that study were typically very low and we also note that none
of our cohort had any reported history of bacteremia/bacterial-endocarditis. It is important
in this regard that our qPCR assay was very sensitive (LOD = 5 copies/50ng DNA) and al-
lowed for the detection of gram-positive bacteria such as S. gallolyticus by the addition of lyso-
zyme to the homogenized human tissue prior to DNA extraction; this suggests that the
Table 3. Clinicopathological characteristics of the cohort of fresh-frozen tissues (N = 55).
Feature (patients with missing data) Number of patients N = 55
Mean age (2) 59 (SD±15.3)


















Ascending colon 1 (2%)
Hepatic flexure 1 (2%)
Transverse colon 3 (6%)
Splenic flexure 1 (2%)
Descending colon 3 (6%)
Sigmoid colon 3 (6%)
Rectosigmoid junction (RSJ) 4 (8%)
Rectum 30 (60%)








In the case of age and BMI mean values and their standard deviations (SD) are reported. The numbers in
column 1 in brackets represent the number of patients with missing data in each category.
doi:10.1371/journal.pone.0119462.t003
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discrepancy between our results and those of Abdulamir et al. might be explained by a) differ-
ences in sample preparation, b) ethnic differences in the susceptibility to colonization by
S. gallolyticus or c) geographical differences in S. gallolyticus strains found in Southern Africa
that may have precluded detection of the bacterium in our cohort. Further investigation is
therefore required to clarify this discrepancy.
Of the bacteria that we detected, Fusobacterium was by far the most common, occurring
in 82% and 81% of paired tumour and normal samples, respectively, with 80% concurrent
colonisation in paired samples. Fusobacterium was also the only bacterium that was signifi-
cantly higher in tumour compared to normal samples (p = 6e-5, Wilcoxon signed rank test),
which is in agreement with previous studies [5,7,45]. The qPCR results are summarized in
Fig. 2 and Table 4.
We sequenced Fusobacterium amplicons from 10 of the samples in our cohort to confirm
melt curve matches, but could not in all cases determine strain-level identity from these ampli-
cons (data not shown). F. nucleatum is the only Fusobacterium species that has been associated
with CRC in the literature to date so it seems reasonable to suppose that in our study the Fuso-
bacterium spp is F. nucleatum. However, to confirm this would have required a metagenomic
sequencing approach to explore Fusobacterium spp representation in more detail, since it is
not yet known which other Fusobacterium spp. might be relevant to the disease; this was be-
yond the scope of the present study so we refer hereafter exclusively to Fusobacterium spp.
In our cohort, we detected ETBF in 14/54 (26%) of colorectal adenocarcinomas and 15/53
(28%) of adjacent normal mucosa samples and 71% of ETBF+ patients were infected in both
adenocarcinoma and matched adjacent normal samples. This is consistent with previous stud-
ies on faecal samples, which have reported ETBF in ±12% of healthy controls [12,46], 27% of
patients with diarrhea [46], and 38% of patients with CRC [12] with colonisation rates appear-
ing to vary widely by geographical location [30].
Although Balamurugan et al. demonstrated significantly higher levels of faecal E. faecalis in
CRC patients compared to healthy controls [11], to our knowledge, ours is the first study to
quantitatively measure E. faecalis in paired adenocarcinoma (28% E. faecalis-positive) and nor-
mal mucosa samples (18% E. faecalis-positive) with 50% of infected patients being infected in
both adenocarcinoma and matched normal mucosa samples. We did not however find any sig-
nificant clinical associations with E. faecalis colonisation.
To investigate the presence of E. coli genes that are commonly found in AIEC and which
might be relevant to oncogenesis, we quantified the presence of ClB (part of the pks geno-
mic island) and afaC (present in all operons of the afimbrial adhesin family) in paired CRC
samples; pks+ E. coli has previously been detected in 55–67% of CRC patients [22,47], com-
pared to 8% of healthy controls [22]. By contrast, in our cohort, 22% of adenocarcinomas
and 24% of adjacent normal mucosa samples were pks+, and 56% of pks+ patients were in-
fected in both adenocarcinoma and matched normal mucosa samples. We also detected
afaC in 36% and 31% of adenocarcinoma and normal mucosa samples, respectively, and
found that 80% of afaC+ patients were infected in both adenocarcinoma and matched nor-
mal mucosa samples; this is much lower than that found by Prorok-Hamon et al., who
found 67% of CRC patients to be afaC+ compared to 17% of controls [22]. This discrepan-
cy could be explained by our relatively high LOD for afaC and pks. Lastly, in contrast to
Buc et al. [47], who found pks to be more common in distal compared to the proximal
colon, we did not find a significant association between the presence of pks and site of dis-
ease. It should be noted that while we examined the presence of pks and afaC, many other
AIEC-related genes that might be relevant to oncogenesis exist, including cyclomodulins
[47] and lpfA [22].
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Fig 2. qPCR quantification of bacteria in paired patient samples, expressed as log10 bacteria/50ng of patient DNA. Each bar represents one samples
(either tumour or normal) and the order of samples are the same for each bacterium. Red (tumour); blue (normal); *(Not determined).
doi:10.1371/journal.pone.0119462.g002
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ETBF and afaC-positive E. coli are significantly enriched in the colon
compared to the rectum of CRC patients.
As shown in Fig. 3, the presence of ETBF and afaC-positive strains were significantly associated
with the colon compared to the rectum in normal samples (FDR = 0.001 and 0.03, respective-
ly), as well as in tumour samples in the case of ETBF (FDR = 0.002). We did not find any signif-
icant differences in colonisation between the proximal and distal colon for any of the bacteria
in this study.
Colonisation by ETBF and high-level colonisation by Fusobacterium are
associated with late-stage CRC.
As shown in Fig. 4, the presence of ETBF was significantly associated with stage of disease
(Fisher’s exact, FDR = 0.04 and 0.002 for normal and tumour samples, respectively). Similarly,
in the case of Fusobacterium, late stage (III/IV) tumour samples were significantly associated
with high-level colonisation by Fusobacterium (Kruskal-Wallis, FDR = 0.03).
In order to investigate which CRC stages were significantly different in terms of the level of
colonisation by Fusobacterium we used Dunn’s test to compare individual stages in a pairwise
manner. Fusobacterium levels were significantly higher in stage III CRCs compared to stage I
Table 4. Quantification of bacteria in colorectal cancer and adjacent normal tissues.
Pathogen Colonisation rate T (%) Colonisation rate N (%) Concurrent colonisation in T & N (%)
Fusobacterium 58/71 (82%) 48/59 (81%) 43/54 (80%)
AIEC (afaC) 19/53 (36%) 17/54 (31%) 16/20 (80%)
AIEC (pks) 12/54 (22%) 13/55 (24%) 9/16 (56%)
E. faecalis 11/40 (28%) 7/38 (18%) 5/10 (50%)
ETBF 14/54 (26%) 15/53 (28%) 12/17 (71%)
EPEC 6/54 (11%) 3/54 (6%) 3/6 (50%)
S. gallolyticus 0/45 (0%) 0/45 (0%) 0/45 (0%)
T and N denote adenocarcinoma and adjacent normal mucosa, respectively. Rates of concurrent colonisation in T and N samples were calculated as a
fraction of the number of patients who were infected in T and/or N with a particular bacterium.
doi:10.1371/journal.pone.0119462.t004
Fig 3. ETBF and afaC+ E. coli are significantly more prevalent in colon vs. rectal cancers. This applies
to both tumour and normal tissue in the case of ETBF (FDR = 0.002, 0.001, respectively) and normal tissue
only in the case of afaC (FDR = 0.03).
doi:10.1371/journal.pone.0119462.g003
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or II CRCs (p = 0.002 for both comparisons). For ETBF, for which we found a difference in the
presence or absence of ETBF between stages, individual stages were compared in a pairwise
manner using Fisher’s exact test. ETBF was found more frequently in stage III or IV CRCs
compared to stage I or II CRCs (stage I vs. IV p = 0.01; stage II vs. stage IV p = 0.01; stage II vs.
stage III p = 0.003) as well as in the normal mucosa of stage IV CRCs compared to stage I
CRCs (stage I vs. IV p = 0.01; stage II vs. IV p = 0.01).
High-level colonisation by Fusobacterium also seems to correlate with chronic inflamma-
tion in CRC. For example, McCoy et al. found a significant positive correlation between Fuso-
bacterium species abundance and local inflammation in adenoma cases [6] whilst we found
that there is a trend towards high-level colonisation by Fusobacterium in patients with noted
inflammation in normal tissue (Kruskal-Wallis test, p = 0.01, FDR = 0.07) (Fig. 5) and tumour
tissue (Kruskal-Wallis, p = 0.18, FDR = 0.2). We also found a positive association between high
levels of colonisation by Fusobacterium and pks-positve E. coli in normal tissue (Fisher’s exact,
FDR = 0.007) or EPEC in tumour tissue (Fisher’s exact, p = 0.08, FDR = 0.2). These data sug-
gest that certain individuals may be more susceptible to bacterial colonisation and inflamma-
tion of the normally sterile colonic epithelium.
Further clinical associations with high-level colonisation by
Fusobacterium
We found a significant relationship between high-level colonisation by Fusobacterium and
MSI-H, compared to samples that were MSS or MSI-L (Kruskal-Wallis, FDR = 0.05), Fig. 5.
We also found a significant increase in Fusobacterium levels in CRCs of younger patients
(< 60 years), (Kruskal-Wallis, FDR = 0.03) with 31% vs. 11% of patients under or over the age
of 60 falling into the Fusobacterium-high group of colonisation (Fig. 5). In normal samples, we
also noted a trend towards high-level colonisation in males compared to females (Kruskal-
Wallis, p = 0.05), but this was not significant after multiple testing correction, Fig. 5.
In order to objectively assess the levels of colonisation by Fusobacterium between different
ethnic groups we used subsets of the data to account for the significant difference in patient age
by ethnicity (ANOVA p = 7.2e-6); across all patients, the mean age of black patients was 36,
that of mixed ancestry patients was 58, and that of white patients was 77. We therefore per-
formed two age- and gender-matched comparisons: a) black patients (mean age = 35, N = 6)
vs. mixed ancestry patients under the age of 50 (mean age = 42, N = 10) and b) caucasian
Fig 4. ETBF and Fusobacterium are found at significantly higher levels in late stage (III/IV) cancers. For Fusobacterium, individual stages were
compared in a pairwise manner using Dunn’s test. For ETBF, individual stages were compared in a pairwise manner using Fisher’s exact test.
Fusobacterium is found at significantly higher levels in stage III CRCs compared to stage I or II CRCs. ETBF is found more frequently in stage III or IV CRCs
compared to stage I or II CRCs; and in the corresponding normal mucosa of stage IV CRCs compared to stage I CRCs.
doi:10.1371/journal.pone.0119462.g004
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patients (mean age = 77, N = 8) vs. mixed ancestry patients over the age of 70 (mean age = 72,
N = 19). Fusobacterium was found at significantly higher levels in black patients compared to
their age-matched mixed ancestry counterparts in adjacent normal samples, (Kruskal-Wallis,
p = 0.03, Fig. 5), but not in tumour samples (Kruskal-Wallis, p = 0.6). No significant differences
Fig 5. Fusobacterium clinicopathological associations. High-level colonisation by Fusobacterium is significantly more prevalent in younger patients,
males and patients of Black ethnicity. Due to the disproportionately high number of young, black patients seen in our cohort the relationship between ethnicity
and levels of colonisation by Fusobacterium was assessed using the subset of patients 50 years. A borderline significant relationship was seen between
high-level colonisation by Fusobacterium and MSI-H compared to MSS/MSI-L (In our cohort three MSI-L cases were included with the MSS cohort). The
vertical and horizontal dotted lines in the bottom right Fig. represent the cutoff for high-level colonisation by pks+ E. coli and Fusobacterium, respectively (see
methods for further detail). FB: Fusobacterium; B: Black; C: Caucasian; I: Indian; M: Mixed Ancestry; N: normal tissue; F: Female; M: Male.
doi:10.1371/journal.pone.0119462.g005
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were found between age-matched caucasian and mixed ancestry patients in terms of Fusobac-
terium colonisation levels.
Finally, the Fusobacterium-high group was also significantly associated with the presence of
pks-positive E. coli in normal samples (Fisher’s exact, FDR = 0.01) and two of the three EPEC+
tumours were also infected with Fusobacterium-high (Fisher’s exact, p = 0.08, FDR = 0.2),
Fig. 5.
EPEC detection and characterisation
In the fresh-frozen cohort, we detected EPEC via the intimin gene (eaeA) in 11% and 6% of tu-
mour and normal samples, respectively; with 50% concurrent colonisation in paired samples.
Colonisation levels varied from ±13–3037 bacteria/50ng of DNA extracted. Notably, all EPEC-
positive cases (N = 6) were identified as atypical EPEC (aEPEC) by screening for bfpA (present
in typical EPEC) and stx1 (present in shiga-toxin producing E. coli (STEC)), neither of which
were present in any of our samples. aEPEC has not been previously reported in association
with CRC, although the EPEC detected in FFPE CRC samples by Maddocks et al. [25] could be
aEPEC since they only profiled eaeA, and not bfpA or stx1.
No significant clinical associations were found for EPEC––this is not surprising given the
small number of EPEC positive patients (N = 6). However, of the six patients infected with
EPEC, 67% (2/3) of sporadic MSI-H cases (fresh-frozen cohort), and only 9% (2/22) of MSS
were EPEC-positive; the remaining two EPEC-infected patients were of unknown MSI status.
Therefore, similar to Fusobacterium, there seems to be a trend towards colonisation by EPEC
in sporadic MSI-H patients. Furthermore, in light of the effect of intimin subtype (of which
there are currently 27 known variants [48]) on tissue tropism [49–51] we sequenced the 150bp
amplicon amplified during intimin detection, which is located in the variable region of intimin
and identified intimin theta exclusively in the two EPEC-positive MSI-H cases and in one case
with unknown MSI-status. In the remaining EPEC-positive samples, intimin subtype could not
be conclusively identified based on the 150bp product, but produced equal BLAST scores for
the intimin subtypes: zeta 2&3, alpha 2, pi, iota 1, delta, beta 2, epsilon 2&8, jota and lambda in
all of the remaining samples. In samples with concurrent colonisation in paired samples, the
150bp product sequences were identical. Intimin sequencing results are summarized in
Table 5.
Our finding that intimin theta was exclusively identified in MSI-H EPEC positive cases
(both located in the caecum), and in one case of unknown MSI status (located in the rectum) is
interesting. Moreover, the two MSI-H patients infected with intimin-theta aEPEC were also
the only two patients (with available MSI data) whereMLH1 was hypermethylated, as deter-
mined by methylation-specific qPCR. Both these patients were also infected with high levels of
Fusobacterium (2730 and 68700 copies/50ng in tumour samples). Our data contrast with the
work of Maddocks et al. who recently demonstrated in vitro EPEC-induced depletion of the
mismatch repair proteins occurring at the protein level, despite an apparent increase inMLH1
andMSH2mRNA following infection of HT29 cells with EPEC (strain E2348/69) [21]. Mad-
docks et al. concluded that EPEC-induced depletion of MLH1 and MSH2 proteins was depen-
dent on mitochondrial targeting of the EPEC effector protein EspF and that this depletion
significantly increased the mutational frequency of infected cells [21]. Further work therefore
seems needed to reconcile the apparently differing molecular origins of MLH1 protein deple-
tion suggested by the cell-line-based studies of Maddocks et al. and our studies on
clinical samples.
Lastly, although we did not sequence the entire intimin gene, the 150bp amplified sequences
were consistently identical within but not between patients, suggesting that strains isolated
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from tumour or normal biopsies from a given patient are identical, in agreement with the find-
ings by Martin et al. concerning E. coli strains in paired CRC samples [26].
Next, given the reported relationship between EPEC andMSI in vitro [21,25] as well as the re-
lationship between intimin theta+ aEPEC andMSI seen here, we sourced 18 additional MSI-H
samples from archival FFPE samples. However, none of which tested positive for EPEC, but be-
cause the median level of EPEC colonisation across EPEC-positive samples from the fresh-fro-
zen cohort was relatively low (51 copies/50ng DNA), we investigated whether the level of
degradation in the FFPE samples precluded detection in these samples. To this extent we com-
pared the qPCR results from fresh-frozen (150bp amplicon) and matched archival FFPE samples
(70 bp amplicon) for three EPEC-positive patients (5 EPEC-positive T or N samples). EPEC
could only be detected in one of the five matched FFPE samples––the sample that displayed the
highest level of colonisation (3037 copies/50ng) in the fresh frozen tissue. Further, the median
estimated LOD for the FFPE samples was 191 copies/50ng DNA (see Methods for further de-
tails), which is higher than the median level detected in fresh frozen samples (51 copies/50ng
DNA). We therefore conclude that if EPEC were present in the MSI-H FFPE samples at levels
similar to that seen in fresh-frozen samples, the level of degradation in the FFPE samples would
have precluded detection of EPEC, even when attempting to amplify a 70bp amplicon.
Discussion
There are an increasing number of reports in the literature of specific bacteria enriched in CRC
patients compared to healthy controls. Here, our goal was to simultaneously characterise these
bacteria across a single cohort in both tumour and histologically normal (as identified by a
qualified anatomical pathologist) adjacent tissue in order to gain a better understanding of col-
onisation patterns in CRC patients. By quantifying multiple CRC-associated bacteria in one co-
hort, we have been able to uncover inter- and intra-individual patterns of colonisation not
previously recognised. We further identified significant associations with clinicopathological
features including MSI-H (Fusobacterium), stage of disease (ETBF and Fusobacterium), tu-
mour location (ETBF and afaC-positive E. coli), age (Fusobacterium), as well as a positive asso-
ciation between Fusobacterium and pks-positive strains.
Table 5. Summary of BLAST search query to identify intimin subtypes.








44T theta 100 MSI-H Y Y
44N theta 99 MSI-H N Y
63T theta 100 MSI-H Y NA
34N zeta 2&3, alpha 2, pi, iota 1, delta, beta 2, epsilon
2&8, jota, lambda
100 MSS N Y
34T zeta 2&3, alpha 2, pi, iota 1, delta, beta 2, epsilon
2&8, jota, lambda
100 MSS N Y
22T theta, gamma 98 ND ND NA
45T zeta 2&3, alpha 2, pi, iota 1, delta, beta 2, epsilon
2& 8, jota, lambda
97 ND ND NA
29N zeta, alpha 2, pi, iota 1, delta, beta 2, epsilon, jota,
lambda
100 MSS ND Y
29T zeta 2&3, alpha 2, pi, iota 1, delta, beta 2, epsilon2&
8, jota, lambda
100 MSS ND Y
Samples highlighted in bold were used to determine the effect of FFPE fixation on the ability to detect EPEC by qPCR. ND: not determined.
doi:10.1371/journal.pone.0119462.t005
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Notably, our finding that late stage (III) tumour samples were significantly associated with
high-level colonisation by Fusobacterium is consistent with previous studies demonstrating a
positive association between high-level colonisation by Fusobacterium and regional lymph
node metastases [5,45]. Bonnet et al. found a similar trend between cyclomodulin-positive
E. coli, and stage III/IV colon cancers, which we however did not observe here [52]. Tumour
tissue provides a nutrient-rich surface that is not protected by an intact mucosal layer, and the
tumour-homing activity of certain bacteria is well documented [53], but this does not necessar-
ily imply oncogenic potential. However, in addition to the enrichment of Fusobacterium in tu-
mour vs. normal tissues and in late stage CRCs, Fusobacterium spp. are also enriched in
irritable bowel disease (IBD) patients (who have a 2–3 fold increased risk of developing CRC)
[54] compared to healthy controls. Interestingly, Fusobacterium spp. isolated from inflamed
tissue in IBD patients were significantly more invasive in a subsequent in vitro assay compared
to non-inflamed tissue from IBD patients or healthy controls [55], possibly suggesting an active
role for Fusobacterium in gastrointestinal diseases.
Our finding that Fusobacterium levels positively correlate with MSI-H, younger age and
black ethnicity may be particularly relevant in the South African setting where a disproportion-
ately high number of young black CRC patients––41–57% of black CRC patients [56–58] com-
pared to only 10% of white CRC patients under the age of 50 [56]–has been reported. CRCs in
young black patients do not appear to originate from colonic polyps [57] and have not been
linked to IBD or diverticulosis [57]; the majority of these cancers are located in the proximal
colon [56–58] (often in the caecum [57]), and often display mucinous histology [58,59] and a
higher rate of microsatellite instability (MSI) compared to older patients [56,59]. Our findings
may therefore suggest a genetic aspect to susceptibility to high-level colonisation by Fusobac-
terium, which warrants further investigation in a larger cohort.
Tahara et al. have previously observed an association between high-level colonisation by
Fusobacterium and MSI-H,MLH1methylation as well as the CpG island methylator pheno-
type (CIMP) [45] suggesting that Fusobacteriummight promote MSI by inducingMLH1
hypermethylation. Importantly, the association between MSI and Fusobacterium observed here
was independent of the origin of MSI in our cohort, with 4/8 HNPCC adenocarcinoma samples
falling into the Fusobacterium-high group of colonisation. HNPCC requires inactivation of
both alleles of the affected mismatch-repair gene and it is possible that Fusobacterium precipi-
tates loss of the wild-type allele through methylation. However, the role of aberrant methyla-
tion in the aetiopathogenesis of HNPCC remains questionable: Kaz et al. found promoter
methylation ofMLH1 in 53% of HNPCC adenomas [60], compared to only 4% of sporadic ad-
enomas, whilst Speake et al. found 40% and 25% of hyperplastic polyps of sporadic or HNPCC
origin to be CIMP-H [61]. However, LOH or gene conversion are the most frequent mecha-
nism of inactivation of the wild typeMLH1 allele in HNPCC tumours [62–66]. Further,
HNPCC and sporadic MSI-H cancers have distinct histological and molecular features: While,
both cancer types display lymphocytic infiltration, mucin secretion and poor differentiation
[67], HNPCCs tends to originate from classical adenomas compared to sessile-serrated adeno-
mas in the case of MSI-H CRCs [68]; on a molecular level, HNPCCs are strongly associated
with mutations in APC or ß-catenin and/or KRAS [67,68], while MSI-H sporadic CRCs instead
exhibit BRAFmutations, which are present in CRC precursor lesions [68]. Therefore, while it
is possible that Fusobacteriummight cause MSI (and thereby CRC), it seems more likely that
Fusobacterium preferentially flourishes in MSI-H compared to MSS cancers, perhaps due to
the altered glycosylation profile in MSI-H cancers [69], that could facilitate adherence of cer-
tain bacteria [70]. Additionally, F. nucleatum infection has been shown to stimulate prolifera-
tion in CRC- but not in non-neoplastic-cell lines [16] and, Fusobacterium spp. have been
demonstrated to stimulate cellular proliferation following an initial oncogenic hit (affecting a
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component of the WNT signaling pathway) in mice [71] and in CRC cell lines [16]. Taken to-
gether, it therefore seems most likely that Fusobacterium is not oncogenic itself, but may con-
tribute to tumourigenesis by promoting inflammation and cancer cell proliferation.
It has long been appreciated that certain individuals are more susceptible to aberrant patho-
genic colonization of the gut epithelium, which may be accompanied by chronic inflammation,
for example in patients with IBD. However, our finding that colonisation by certain bacteria are
significantly associated with clinicopathological features in CRC—including the stage and site
of disease—is new and might be linked to differential susceptibilities in relation to clinical fea-
tures, such as age and ethnicity; these association do not necessarily imply oncogenicity since
many of the CRC-associated bacteria investigated in this study are asymptomatically present in
a significant percentage of the population [12,46]. One might therefore expect a pathogenic
trend similar to that ofH. pylori where genetic, environmental and strain-specific risk modifiers
govern susceptibility to bacterially-mediated oncogenesis in the colon and where only a small
fraction of individuals infected with the bacterium will eventually develop cancer. Evaluating
the distribution of bacteria in relation to ethnicity, lifestyle- and clinicopathological factors is
the first step in evaluating host-susceptibility to infection and putative bacterially-mediated on-
cogenic mechanisms. Furthermore, bacterial abundance is not the only factor that may be cor-
related with clinicopathological features since low-abundant bacteria may exert a significant
effect on the host through the secretion of toxins at high levels. For example, Dutilh et al.
showed that Enterobacterial toxins were among the most highly expressed in metatranscrip-
tomic sequencing data from CRC paired tumour and normal tissues [72], including toxins from
E. coli, Salmonella enterica and Shigella flexneri [72]. Evaluating the presence of bacterial toxins
with oncogenic potential at the transcriptional or proteomic level will thus provide an addition-
al layer of information to unravel complex host-pathogen interactions with relevance to CRC in
the future. Future studies should also be aimed at validating our findings in a larger cohort (par-
ticularly in MSI-H CRCs in the case of EPEC); and at profiling Fusobacterium at the species
level, as well as other AIEC toxins implicated in CRC not examined here, such as lpfA.
Establishing causality for any of the bacteria examined here remains a challenge and would
require rigorous investigation in animal models as well as large scale epidemiological data, as
was used in establishing causality in the case ofH. pylori and gastric cancer. However, by evalu-
ating the distribution of bacteria in relation to ethnicity, lifestyle- and clinicopathological fac-
tors in a South African cohort, we have taken a first step towards this goal and we expect that
our data will facilitates the development of targeted research questions for future studies.
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